PUBLIC COMPANY
saveBOEHRINGER INGELHEIM
USupdated 12d ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Unknown
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1A Study in Healthy Men to Test Whether Food Influences the Amount of BI 3731579 in the Blood
- —Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France
- phase1A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3
- phase3A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)
- —Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
- phase1A Study in Healthy Men to Test How Well Different Doses of BI 3731579 Are Tolerated
- phase2A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema
- phase2PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
🐶 Hiring Signal
Where BOEHRINGER INGELHEIM is staffing up — a leading indicator of pipeline and commercial priorities.
News
- After billions in deals, Insilico CEO promises: ‘You haven't seen anything yet’Insilico Medicine CEO Alex Zhavoronkov’s mad dash across the BIO International Convention in June attracted plenty of eyes. But the executive would prefer industry watchers gawk at the billions of…biospace · 19h ago
- A COPD drug from China draws $115M in venture fundingExpedition Therapeutics, which has raised nearly $300 million to date, is studying a drug it believes to have notable advantages over other COPD treatments either in development or on the market.biopharma_dive · 6d ago
- Chutes & Ladders—Legend CEO departs without successor in placeLegend Biotech CEO Ying Huang, Ph.D., has left the company suddenly, without a predecessor in place. Huang was elevated from CFO to CEO in 2020 after a Chinese customs investigation was opened on f…fiercebiotech · 12d ago
- ‘Reverse mergers are increasingly popular’: Caldera hops on Synlogic’s Nasdaq listingCaldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.fiercebiotech · 13d ago
- Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assetsLupin has spun out two clinical-phase cancer drug candidates to create Kaveri Therapeutics, a U.S.-based startup that plans to raise cash for further development. Kaveri’s programs hit targets purs…fiercebiotech · 22d ago
- How well are AI-discovered drugs faring in the clinic?Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted development.biopharma_dive · 25d ago
- Novartis cuts New Jersey jobs; OTR, LG Chem explore China cancer drugsPlus news about Seres, Biocytogen, Whitehawk, Boehringer Ingelheim, Prime Vector and MindRank. ⚠️ Novartis reduces New Jersey headcount: A WARN notice for the state notes that 322 employees in East…endpoints · 1mo ago
- A PureTech startup banks $180M for a new IPF drugCelea, backed by investors such as RA Capital and Leaps by Bayer, is making what it says is an improved version of Roche's Esbriet.biopharma_dive · 1mo ago
- STAT+: An obesity drug deep-dive, and peptides move mainstreamCan any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…stat · 2mo ago
- Major readouts from the annual diabetes conferenceWhy "Schedule F" matters, the Ebola outbreak response, and more health news from Morning Roundsstat · 2mo ago
comments(0)
5-min edit window · permanent after that